HeartSciences Inc.

On* March 11, 2026,we and Streeterville amended the$2.5M* Streeterville Note to extend the maturity date to* June 30, 2026.On June 23, 2026,the Company entered into an exchange agreement with Streeterville, pursuant to which Streeterville exchanged the remaining balance of accrued interest of approximately$164,017* owed under the*$2.5M* Streeterville Note for78,103 shares of the Company's Common Stock. The issuance of the shares was made pursuant to the exemption from the registration requirements afforded by Section3(a)(9) of the Securities Act. As of the date of this Annual Report, the*$2.5M* Streeterville note and accrued interest has been repaid in full.

Director and Executive Officer Adoption, Modification or Termination of10b5-1 Plans in Fiscal Quarter Ended April 30, 2026****

Our Section16 officers and directors* mayenter into plans or arrangements for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule10b5*-1(c) of the Exchange Act. Such plans and arrangements must comply in all respects with our insider trading policies, including our policy governing entry into and operation of10b5-1 plans and arrangements.

During fiscal quarter ended* April 30, 2026,none of our Section16* officers adopted Rule10b5-1 trading arrangements (as defined in Item408 of Regulation S-K of the Exchange Act), andno plans were modified or terminated during such period.